Description: Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company has leveraged its expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus and COVID-19.
Home Page: valneva.com
VALN Technical Analysis
6 rue Alain Bombard
Saint-Herblain,
44800
France
Phone:
33 2 28 07 37 10
Officers
| Name | Title |
|---|---|
| Mr. Thomas Lingelbach | Chairman of the Management Board, Pres & CEO |
| Mr. Franck Grimaud MBA | Director Gen., Chief Bus. Officer & Member of Management Board |
| Mr. Frederic Jacotot | VP of Legal & IP, Gen. Counsel, Corp. Sec. and Member of Management Board |
| Dr. Juan-Carlos Jaramillo M.D. | Chief Medical Officer & Member of the Management Board |
| Mr. Peter Buhler | CFO & Management Board Member |
| Mr. Perry Celentano | Interim Chief Operating Officer |
| Ms. Dipal Patel | Chief Commercial Officer & Member of Management Board |
| Mr. Joshua Drumm Ph.D. | VP of Investor Relations |
| Ms. Laetitia Bachelot-Fontaine | VP of Global Communications & European Investor Relations |
| Mr. Gerald Strohmaier | VP of Human Resource |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 7.7705 |
| Price-to-Book MRQ: | 5.7635 |
| Price-to-Sales TTM: | 2.0179 |
| IPO Date: | 2021-05-05 |
| Fiscal Year End: | December |
| Full Time Employees: | 762 |